Skip to main content
LQDA
NASDAQ Life Sciences

Director-Affiliated Entity Files to Sell $13M in Liquidia Stock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$62.5
Mkt Cap
$5.562B
52W Low
$11.85
52W High
$66.24
52W Position info
427% above low
Off High info
5.6% below high
Rel. Volume info
3.1× avg
Market data snapshot near publication time

LQDA has more than doubled off its 52-week low of $11.85 on elevated volume (3.1× avg).

Summary

A director-affiliated entity, Canaan VIII LP, plans to sell $13 million in Liquidia Corp stock, continuing a trend of significant insider sales.


Key Events · Ownership and Investor Activity · LQDA

  • Intent to Sell $13 Million in Stock

    Canaan VIII LP, a director-affiliated entity, has filed a Form 144 to sell 200,000 shares of Liquidia Corp common stock, valued at approximately $13 million.

  • Continuation of Recent Sales

    This proposed sale follows a previous disposition of 318,893 shares by Canaan VIII LP on May 11, 2026, which generated $15 million in gross proceeds.

  • Part of Broader Insider Distribution

    The filing contributes to a pattern of significant insider selling at Liquidia Corp, with over $66 million in open-market sales by 11 active insiders in the last 90 days.


Analysis · LQDA · Life Sciences

Canaan VIII LP, an entity affiliated with a director, has filed a Form 144 indicating its intent to sell an additional $13 million worth of Liquidia Corp common stock. This follows a previous sale of $15 million by the same entity on May 11, 2026, and contributes to a broader pattern of significant insider distribution observed over the past 90 days. This ongoing selling pressure from a director-affiliated entity could be perceived negatively by the market.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LQDA was trading at $62.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.6B. The 52-week trading range was $11.85 to $66.24. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LQDA - Latest Insights

LQDA
Nov 10, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $47.45
Real-time Price: $54.78 info
Change: +$7.33 (+15%) info
Market Cap: $4.942B info
LQDA
Nov 10, 2026, 6:45 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $47.40
Real-time Price: $54.78 info
Change: +$7.38 (+16%) info
Market Cap: $4.942B info
LQDA
Nov 10, 2026, 6:30 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $50.00
Real-time Price: $54.78 info
Change: +$4.78 (+10%) info
Market Cap: $4.942B info
LQDA
Oct 13, 2026, 9:49 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $39.50
Real-time Price: $54.78 info
Change: +$15.28 (+39%) info
Market Cap: $4.942B info
LQDA
Oct 13, 2026, 5:50 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $31.76
Real-time Price: $54.78 info
Change: +$23.02 (+72%) info
Market Cap: $4.942B info